Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening Products

UK's NICE Recommends Use Of Erbitux For Metastatic Colorectal Cancer Patients
The United Kingdom"s National Institute for Health and Clinical Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending the use of the drug Erbitux® (cetuximab) in combination with chemotherapy as a first-line treatment for patients with metastatic (advanced) colorectal cancer (mCRC) who have met specific additional criteria(1) - presenting the possibility of potentially curative surgery.(2) The treatment is recommended for patients in whom the cancer has spread only to the liver and who have normal or "wild-type" KRAS tumors.(1) In the UK, a recommendation by NICE is a prerequisite for funding of a medical treatment by the National Health Service.
generic viagra online
University Of Queesnland's Speech Pathology Students Teach The Art Of Smooth Talking, Australia
A group of UQ speech pathology students recently ran an intensive treatment program for people who stutter.
News of the day
Hormonal Therapies Offer Effective Solutions For Many Adult Women With Acne
Although acne traditionally has been considered a disease of teenagers, it is also extremely common in adult women. Studies show that acne affects more than 50 percent of women between the ages of 20-29 and more than 25 percent of women between the ages of 40-49 (1). In fact, after age 20, women are far more likely to report having acne than men. While there is no cure for acne, dermatologists are finding that hormonal therapies can help some women fight bothersome acne that occurs in adulthood.
Endocrinology

University Of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections Missed By Standard Hybridization Test

to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the Company"s ability to develop and commercialize new technologies and products, particularly new technologies such as HPV DNA diagnostics and laboratory developed tests, reliance upon the collaborative efforts of other parties, the Company"s ability to manage its existing cash res or raise additional cash res, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, and other risks detailed from time to time in the Company"s Annual Report on Form 10-K for the year ended December 31, 2008 and periodic reports and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release. SEQUENOM

Pages: 1 [2] 


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009